Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal

Journal of Pineal Research

Volumn 59, Issue 1, 2015, Pages 60-69

  Xiang, Shulin ^a   Dauchy, Robert T ^a   Hauch, Adam ^a   Mao, Lulu ^a   Yuan, Lin ^a   Wren, Melissa A ^a,b   Belancio, Victoria P ^a   Mondal, Debasis ^a   Frasch, Tripp ^a   Blask, David E ^a   Hill, Steven M ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

Author keywords

breast; circadian; doxorubicin; melatonin; warburg

Indexed keywords

ABC TRANSPORTER; DOXORUBICIN; ESTROGEN RECEPTOR ALPHA; MELATONIN; PHOSPHOTRANSFERASE; TRANSCRIPTION FACTOR; GLUCOSE; OXYGEN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CIRCADIAN RHYTHM; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; LIGHT DARK CYCLE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ANIMAL; BREAST NEOPLASMS; DRUG RESISTANCE; DRUG SCREENING; LIGHT; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; NUDE RAT; RADIATION RESPONSE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CIRCADIAN RHYTHM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUCOSE; HUMANS; LIGHT; MCF-7 CELLS; MELATONIN; MICE, NUDE; OXYGEN; RATS; RATS, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84934296827     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12239     Document Type: Article

References (49)

1. Austreid E, Lonning PE, Eikesdal HP,. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opin Pharmacother 2014; 5: 681-700.
2. Gariboldi MB, Ravizza R, Ruganti L, et al., Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int J Oncol 2003; 22: 1057-1064.
3. Singal PK, Iliskovic N, Li T,. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997; 11: 931-936.
4. Gewitz DA,. critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
5. Heger Z, Cernei N, Kudr J, et al., A novel insight into the cardiotoxicity of antineoplastic drug doxorubicin. Int J Mol Sci 2013; 14: 21629-21646.
6. Gonzalez AM, Morales-Vasquez F, Hortobagyi GN,. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
7. Tavares-Valente D, Baltazar F, Moreira R, et al., Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin. J Bioenerg Biomembr 2013; 5: 467-475.
8. Hua G, Liu Y, Li X, et al., Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A. Oncol Rep 2014; 6: 2727-2734.
9. Burris HA,. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013; 4: 829-842.
10. Roskoski R,. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014; 79: 34-74.
11. McCubrey JA, Steelman LS, Chappell WH, et al., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
12. Li Q, Mullins SR, Sloane BF, et al., P21-activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia 2008; 10: 314-328.
13. Romeo Y, Zhang X, Roux PP,. Regulation and function of the RSK family of protein kinases. Biochem J 2012; 441: 553-569.
14. Sims JT, Ganguly SS, Bennett H, et al., Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS ONE 2013; 8: e55509.
15. Lee SA, Karazkiewicz JW, Anderson WB,. Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Res 1992; 52: 3750-3759.
16. Diaz-Bessone MI, Berardi DE, Campodonico PB, et al., Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs. Breast Cancer Res Treat 2011; 126: 577-587.
17. Gottesman MM, Fojo T, Bates SE,. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
18. Zhang W, Ding W, Chen Y, et al., Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin 2011; 43: 647-653.
19. Kassner N, Huse K, Martin HJ, et al., Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 2008; 36: 2113-2120.
20. Novotna R, Wsol V, Xiong G, et al., Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett 2008; 181: 1-6.
21. Joerger M, Huitema AD, Meenhorst PL, et al., Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemother Pharmacol 2005; 55: 488-496.
22. Ferrazzi E, Woynarowski JN, Arakali A, et al., DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin. Cancer Commun 1991; 3: 173-180.
23. Olson RD, Mushlin PS, Brenner DE, et al., Doxorubicin cardiotoxicity may be due to its metabolite, doxorubicinol. PNAS USA 1988; 85: 3585-3589.
24. Arendt J,. Melatonin and human rhythms. Chronobiol Int 2006; 23: 21-37.
25. Hill SM, Blask DE, Xiang S, et al., Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia 2011; 16: 235-245.
26. Dauchy RT, Xiang S, Mao L, et al., Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen in breast cancer. Cancer Res 2014; 74: 4099-4119.
27. Blask DE, Dauchy RT, Dauchy EM, et al., Light exposure at night disrupts host/cancer circadian regulatory dynamics: Impact on the Warburg effect, lipid signaling and tumor growth prevention. PLoS ONE 2014; 9: e102776.
28. Blask DE, Brainard GC, Dauchy RT, et al., Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005; 65: 11174-11184.
29. Lazennec G, Thomas JA, Katzenellenbogen BS,. Involvement of the cAMP response element binding protein (CREB) and estrogen receptor phosphorylation in the synergistic action of the estrogen receptor by estradiol and protein kinase activators. J Steroid Biochem Mol Biol 2001; 77: 193-203.
30. Dziegiel P, Jethon Z, Suder E, et al., Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp Toxicol Pathol 2002; 53: 433-439.
31. Lin MC, Yin MC,. Preventive effects of ellagic acid against doxorubicin-induced cardio-toxicity in mice. Cardiovasc Toxicol 2013; 13: 185-193.
32. Marquette C, Mabell L,. Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol 2012; 13: 263-275.
33. Hua G, Lin Y, Li X, et al., Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A. Oncol Rep 2014; 31: 2727-2734.
34. Slamon DJ, Clark GM, Wong SG, et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
35. Holbro T, Beerli RR, Maurer F, et al., The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100: 8933-8938.
36. Eling TE, Everhart AL, Angerman-Stewart J, et al., Modulation of epidermal growth factor signal transduction by linoleic acid metabolites. Adv Exp Med Biol 1997; 407: 319-322.
37. Chow HY, Jubb AM, Koch HN, et al., p21-activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res 2012; 72: 5966-5975.
38. Higuchi M, Onishi K, Kikuchi C, et al., Scaffolding function of PAK in the PKD-1-Akt pathway. Nat Cell Biol 2008; 10: 1356-1364.
39. Velpula KK, Bhasin A, Asuthkar S, et al., Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res 2013; 73: 7277-7289.
40. Fang B,. Genetic interactions of STAT3 and anticancer drug development. Cancers 2014; 6: 494-525.
41. Lal S, Sandanaraj E, Wong ZW, et al., CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008; 99: 2045-2054.
42. Ohara H, Miyabe Y, Deyashiki Y, et al., Reduction of drug ketones by dihydrodiol dehydrogenase, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 1995; 50: 221-227.
43. Martin V, Sanchez-Sanchez AM, Herrera F, et al., Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 2013; 108: 2005-2012.
44. Klement GL, Goukassian D, Hlaty L, et al., Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart. Front Pharmacol 2012; 3: 113.
45. Mamillapalli R, Vanhouten J, Zqwalich W, et al., Switching of G-protein usage by the calcium-sensing receptor reverses its effect on parathyroid hormone-related protein secretion in normal versus malignant breast cells. J Biol Chem 2008; 283: 24435-24447.
46. Lee V, Randhawa AK, Singal PK,. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am J Physiol 1991; 261: H989-H995.
47. Sarvazyan NA, Askari A, Huang WH,. Effects of doxorubicin on cardiomyocytes with reduced level of superoxide dismutase. Life Sci 1995; 57: 1003-1010.
48. Reiter R, Tang L, Garcia JJ, et al., Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci 1997; 60: 2255-2271.
49. Ahmed HH, Mannaa F, Elmegeed GA, et al., Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity. Bioorg Med Chem 2005; 13: 1847-1857.